Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119966) titled 'Analgesic Efficacy and Safety of Nalbuphine in Patients Undergoing Transarterial Chemoembolization for Liver Cancer' on March 6.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Shenzhen Traditional Chinese Hospital
Condition:
primary hepatocellular carcinoma
Intervention:
Nalbuphine group:None
Recruitment Status: Not Recruiting
Phase: Retrospective study
Date of First Enrollment: 2025-11-01
Target Sample Size: Nalbuphine group:30;Flurbiprofen ester group:30;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=306529
Publis...